Zydus Lifesciences gets tentative approval for Sugammadex injection

16 Sep 2022 , 01:15 PM

Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. The company said that the drug will be manufactured at the groups injectables manufacturing facility at Jarod, India. According to IQVIA MAT July 2022 data, Sugammadex injection had annual sales of $772 million in the United States. The group now has 323 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04, the drug maker stated. Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit fell 11.7% to Rs 518.3 crore on a 1.8% increase in total income from operations to Rs 4,072.7 crore in Q1 FY23 over Q1 FY22. Shares of Zydus Lifesciences were down 1.89% to Rs 364.05 on the BSE. Powered by Capital Market – Live News